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otitis media (oM), a very common disease in young children, can result in hearing loss. in order to 
potentially replicate previously reported associations between oM and PLG, exome and Sanger 
sequencing, RNA-sequencing of saliva and middle ear samples, 16S rRNA sequencing, molecular 
modeling, and statistical analyses including transmission disequilibrium tests (tDt) were performed 
in a multi-ethnic cohort of 718 families and simplex cases with OM. We identified four rare PLG 
variants c.112A > G (p.Lys38Glu), c.782G > A (p.Arg261His), c.1481C > T (p.Ala494Val) and c.2045 T > A 
(p.Ile682Asn), and one common variant c.1414G > A (p.Asp472Asn). However TDT analyses for these 
PLG variants did not demonstrate association with OM in 314 families. Additionally PLG expression is 
very low or absent in normal or diseased middle ear in mouse and human, and salivary expression and 
microbial α-diversity were non-significant in c.1414G > A (p.Asp472Asn) carriers. Based on molecular 
modeling, the novel rare variants particularly c.782G > A (p.Arg261His) and c.2045 T > A (p.Ile682Asn) 
were predicted to affect protein structure. Exploration of other potential disease mechanisms will help 
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elucidate how PLG contributes to oM susceptibility in humans. our results underline the importance 
of following up findings from genome-wide association through replication studies, preferably using 
multi‑omic datasets.
Otitis media (OM) is one of the most common diseases in young children, with 80% of children under the age of 
3 years having at least one episode of acute  OM1. OM with effusion can result in hearing  loss2, and can occasion-
ally lead to an auditory processing  disorder3. The frequent occurrence of this disease continues to be a burden on 
the healthcare system. From 2009 to 2011, 8.6 million emergency department visits resulted in otologic diagnoses 
in the United States, with OM as the most common diagnosis (60.6%) for ear  cases4. This healthcare burden 
results in great costs. Management of OM, including office visits, antibiotics, and surgeries from 1998–2008 was 
estimated to have cost over $5.3 billion annually in the United  States5.
There are multiple known risk factors for OM, such as allergies, viral upper respiratory infection, previous 
history of OM, family history, lack of breastfeeding, multiple siblings, day care attendance, second-hand smoke 
and low social  status6. Despite the public health measures taken to lower these risk factors and reduce the 
incidence of OM, prevalence remains high, suggesting additional factors such as genetic predisposition. Previ-
ous studies have shown a strong correlation between genetic risk factors and both recurrent acute otitis media 
(RAOM) and chronic otitis media with effusion (COME), with heritability estimated from 22–74% based on 
type of OM and  cohort7,8.
In a genome-wide association study (GWAS) involving > 120,000 European-descent individuals, a heterozy-
gous PLG variant c.112A > G (p.Lys38Glu) was associated with childhood ear infections [OR = 1.43; 95%CI = 1.26, 
1.63; p = 3.8 × 10−8] 9. Additionally PLG variants c.112A > G (p.Lys38Glu) and c.1414G > A (p.Asp472Asn) were 
reported to be co-inherited in families with type I plasminogen  deficiency10.
PLG (MIM 173,350) encodes plasminogen which is a secreted blood zymogen that, when activated by prote-
olysis, is converted to plasmin. The product plasmin is a serine protease that degrades fibrin clots and promotes 
degradation of the extracellular  matrix11. Plasminogen has been shown to play a crucial role in other cellular 
processes such as wound healing, immunity, tissue remodeling, inflammation, and cell  migration12. Interestingly, 
there is evidence that some bacteria possess plasminogen-binding adhesins on their cell surface to exploit the 
fibrinolytic system by degrading host junction proteins and initiating signaling events that facilitate bacterial 
uptake and  invasion11,13. In previous studies, mice deficient in plasminogen spontaneously developed chronic 
OM by 18 weeks of age, and local injection of plasminogen led to healing of eardrum  perforations14,15. For these 
mouse studies, only homozygous Plg-deficient mice were examined.
In this study, we want to determine whether individuals with heterozygous PLG variants also have increased 
susceptibility to OM. We aim to identify coding PLG variants co-segregating in families with OM. For the identi-
fied PLG variants, we followed up our findings with phenotypic description, tissue expression and microbiome 
analyses to determine the role that these variants potentially play in OM pathogenesis. Identification of associa-
tions between pathogenic variants and OM will increase the overall understanding of OM susceptibility and the 
mechanisms behind the disease.
Results
PLG variants identified from exome data in multi-ethnic families with OM. We submitted DNA 
samples from 259 multi-ethnic families for exome sequencing. In nine families, we identified four rare and 
damaging PLG variants c.112A > G (p.Lys38Glu), c.782G > A (p.Arg261His), c.1481C > T (p.Ala494Val) and 
c.2045 T > A (p.Ile682Asn), and one common and benign variant c.1414G > A (p.Asp472Asn; Table 1; Figs. 1; 2). 
The variants c.112A > G (p.Lys38Glu) and c.1414G > A (p.Asp472Asn) were both found in two Minnesota fami-
lies and one Finnish trio with an autosomal dominant pattern of inheritance with reduced penetrance (Fig. 1A–
C). For each identified exome variant, Sanger sequencing of the same variant(s) was performed in the rest of 
the relatives of the proband to check for co-segregation. Family UMN48 co-segregates c.112A > G (p.Lys38Glu) 
with OM, however only two out of three affected siblings are heterozygous for c.1414G > A (p.Asp472Asn) due 
to a recombination event between these two variants in the third sibling (Fig. 1A). The second Minnesota family 
UMN469 has incomplete co-segregation for both c.112A > G (p.Lys38Glu) and c.1414G > A (p.Asp472Asn); only 
the affected individuals in the second generation are heterozygous for both variants, while the affected children 
in the third generation are wildtype, which may suggest intra-familial genetic heterogeneity (Fig. 1B) 16,17. Of 
the seven family members of UMN469 that carry the c.1414G > A (p.Asp472Asn) variant, four are unaffected 
with OM (Fig.  1B). The third family is Finnish trio UHF18: the proband has both c.112A > G (p.Lys38Glu) 
and c.1414G > A (p.Asp472Asn), but the mother who also has both c.112A > G (p.Lys38Glu) and c.1414G > A 
(p.Asp472Asn) was normal at examination and has no written record of being affected with OM in childhood 
(Fig. 1C).
The exome data from an affected individual from Pakistani family PKOM18 is heterozygous for c.1414G > A 
(p.Asp472Asn) but this individual does not carry the c.112A > G (p.Lys38Glu) variant. Despite PKOM18 being 
highly consanguineous, Sanger sequencing of the DNA samples from the rest of the PKOM18 family showed 
that the c.1414G > A (p.Asp472Asn) variant co-segregated with OM in an autosomal dominant pattern (Fig. 1D).
Additional rare, predicted-to-be-damaging PLG variants co-segregated with OM in four families (Fig. 2; 
Table 1). In one Minnesota family UMN5014a, the c.2045 T > A (p.Ile682Asn) variant co-segregates with OM. 
However, in this family all relatives with DNA samples including two affected and two unaffected individuals 
carry the c.1414G > A (p.Asp472Asn) variant (Fig. 2A). Three Finnish families have the c.782G > A (p.Arg261His) 
variant (Fig. 2B). Two out of three affected individuals in family UHF48 carry the c.782G > A (p.Arg261His) 
variant. In two Finnish trios, UHF68 and UHF116, the proband is heterozygous for the c.782G > A (p.Arg261His) 
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variant. In both trios the variant was inherited from the father, but the father was considered affected in only one 
of these two trios (Fig. 2B). We identified c.1481C > T (p.Ala494Val) in the exome data for one Finnish individual 
with OM, however DNA was not available for both parents, and therefore we could not verify co-segregation or 
inheritance within that family (pedigree not shown).
In summary, three out of five families with multiple affected relatives co-segregate at least one PLG variant 
with OM. In three trios the PLG variant was inherited, but in only one trio was a parent who transmitted the 
minor allele for the PLG variant labeled as affected. One affected proband without family data carried the minor 
allele for a rare PLG variant.
In the five Finnish families with PLG variants and exome data, five out of the eight affected individuals have 
both RAOM and COME. We also checked an additional 25 Minnesota and 213 Finnish families with exome data 
for additional PLG variants, and only found the common c.1414G > A (p.Asp472Asn) variant in 16 (64%) Min-
nesota and 95 (45%) Finnish families. However the allele counts in these families are not significantly different 
from counts for the c.1414G > A (p.Asp472Asn) variant in non-Finnish European and Finnish gnomAD alleles. 
In Finnish families, no significant association was found between the PLG c.1414G > A (p.Asp472Asn) variant 
and OM type. Additionally, in OM patients from Colorado and Texas, carriage of either c.112A > G (p.Lys38Glu) 
or c.1414G > A (p.Asp472Asn) was not associated with either RAOM or COME. These data suggest that PLG 
variants are not associated with a specific OM type.
Additional non‑oM traits in families with pLG variants. In three Minnesota families with het-
erozygous PLG variants, two of which have [c.112A > G(p.Lys38Glu);c.1414G > A(p.Asp472Asn)] and one with 
[c.2045  T > A(p.Ile682Asn);c.1414G > A(p.Asp472Asn)], a higher proportion of affected individuals have hay 
fever, asthma or allergy, with allergy being significant (Fisher exact p = 0.047). On the other hand, out of five 
Finnish families with PLG variants, in family UHF48 only one of two affected individuals had asthma, as well as 
hypertension and psoriasis. A second family UHF18 had other potentially autoimmune phenotypes such as dia-
betes, nephritis and uveitis. In Pakistani family PKOM18, only one affected relative had eczema. In three Texan 
trios with transmission of the minor allele for the c.112A > G (p.Lys38Glu) variant (Table 2), only one out of six 
variant carriers have allergic rhinitis history. Taken together, these findings do not show a consistent pattern of 
association across cohorts between heterozygous PLG variants and additional traits.
tDt analysis for pLG variants in US trios. In order to potentially replicate OM GWAS findings for PLG, 
the c.112A > G (p.Lys38Glu), c.782G > A (p.Arg261His), c.1481C > T (p.Ala494Val), c.2045 T > A (p.Ile682Asn), 
and c.1414G > A (p.Asp472Asn) variants were Sanger-sequenced in 314 US trios with OM. To determine genetic 
linkage and association, transmission of the minor alleles for these PLG variants were assessed using the trans-
mission disequilibrium test (TDT)18. The minor allele for variant c.782G > A (p.Arg261His) was not present in 
Colorado trios. The minor allele for c.1481C > T (p.Ala494Val) was non-transmitted in one trio and transmitted 
in no trios (Table 2). For c.112A > G (p.Lys38Glu), three alleles were transmitted and four were non-transmitted. 
The variant c.1414G > A (p.Asp472Asn) also had a higher number of non-transmitted alleles, with 101 transmit-
ted and 116 non-transmitted alleles. Lastly, the variant c.2045 T > A (p.Ile682Asn) had one transmitted allele 
and zero non-transmitted. Based on the TDT p-values for all variants, and their combined p value (p = 0.32), 
these variants were not significant in family-based association tests. Based on posthoc power  analysis19, and an 
odds ratio of 1.43 for the PLG variant c.112A > G (p.Lys38Glu) from  GWAS9,our trio study is underpowered to 
detect this small effect size and will require at least 16,200 trios to obtain sufficient power. On the other hand, 
Table 1.  PLG variants identified in nine multi-ethnic families with otitis media. CADD scaled combined 
annotation-dependent depletion score, FA FATHMM, FIN gnomAD finnish, gnomAD genome aggregation 
database, MA mutation assessor, MAF population-matched minor allele frequency, mLR MetaLR, mSVM 
MetaSVM, MT MutationTaster, NFE gnomAD non-Finnish European, PKOM Pakistani family; PP2 PolyPhen2 
HVAR, PR PROVEAN, SAS gnomAD South Asian, SI SIFT, UHF Finnish family, UMN Minnesota family. 
1 mRNA accession number = NM_00301. 2 Damaging prediction from bioinformatics tools in dbNSFP v.3.3a. 
3 Families UMN48, UMN469, and UHF18 have both the c.112A > G (p.Lys38Glu) and the c.1414G > A 
(p.Asp472Asn) variant. In two families UMN469 and UHF48, not all affected individuals carry the PLG 
variant. In one trio UHF18, one unaffected individual carries both variants. 4 Family UMN5014a has both the 
c.1414G > A (p.Asp472Asn) and the c.2045 T > A (p.Ile682Asn) variant. Two unaffected individuals carry the 
c.1414G > A (p.Asp472Asn) variant.
ID hg19  Position1 cDNA variant Amino acid variant rsID Damaging  prediction2 CADD gnomAD MAF
UMN483,  UMN4693,  UHF183 161,127,501 c.112A > G p.Lys38Glu rs73015965 FA,MA,mLR,mSVM, MT,PP2,SI 19.0 NFE = 0.005, FIN = 0.0005
UHF48, UHF68, UHF116 161,137,790 c.782G > A p.Arg261His rs4252187 MA,MT,PP2,PR,SI 27.6 NFE = 0.004, FIN = 0.005
UMN483,  UMN4693, 
PKOM18,  UHF183, 
 UMN5014a4
161,152,240 c.1414G > A p.Asp472Asn rs4252125 – 1.4 NFE = 0.29, SAS = 0.10, FIN = 0.26
UHF520 161,152,819 c.1481C > T p.Ala494Val rs4252128 MA, SI, PP2 26.8 NFE = 0.004,FIN = 0.00004
UMN5014a4 161,162,369 c.2045 T > A p.Ile682Asn rs147175166 FA,MT,PP2,PR 23.3 NFE = 0.001
4Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15035  | https://doi.org/10.1038/s41598-020-70498-w
www.nature.com/scientificreports/
in a previous study we were able to obtain a significant result for a rare FUT2 c.412C > T (p.Arg138Cys) variant 
using the same trio  set16.
Low or absent pLG expression in saliva and middle ear. Plg expression was checked in microarray 
data of wildtype mouse middle ears that were inoculated with non-typeable Haemophilus influenzae (NTHi) vs. 
 control20. Plg expression was low in mouse middle ear. In general, regulation of Plg in the mouse middle ear fol-
lowing infection with NTHi was minimal, although significant down-regulation was observed at a single time 
point at 48 h after inoculation.
From human data from GTEx, PLG is most highly expressed in the liver, with lower expression in the kid-
ney and spleen. However no GTEx data is available on middle ear expression and the four rare PLG variants 
we identified. On the other hand, in GTEx, the common c.1414G > A (p.Asp472Asn) variant is a significant 
expression quantitative trait locus (eQTL) in esophageal mucosa. We previously performed RNA-sequencing of 
19 saliva samples from OM patients in the  US21. In these saliva samples, PLG was expressed at a very low level 
(DESeq2 normalized reads: range 0 to 8.5). A Wilcoxon rank sum test was then used to compare the salivary 
PLG expression for individuals who are wildtype vs. carriers of c.1414G > A (p.Asp472Asn) variant alleles. There 
was no significant difference in PLG expression in saliva in the two groups (data not shown). Likewise PLG was 
Figure 1.  Four multi-ethnic families with the PLG c.112A > G (p.Lys38Glu) and c.1414G > A (p.Asp472Asn) 
variants. Two Minnesota families (A) UMN48 and (B) UMN469 and (C) one Finnish trio UHF18 carry both 
variants with an autosomal dominant pattern of inheritance with reduced penetrance. (D) Despite Pakistani 
family PKOM18 being highly consanguineous, PLG c.1414G > A (p.Asp472Asn) co-segregated with OM in an 
autosomal dominant pattern.
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expressed at a very low level in the cholesteatoma and mucosa samples collected during OM surgery (DESeq2 
normalized reads: range 0 to 8.3, average cholesteatoma 1.96, average mucosa 2.79). Thus in our available samples 
from human saliva and middle ear, PLG expression was very low or absent.
network analysis. The PLG variant c.112A > G (p.Lys38Glu) was identified along with 31 other significant 
loci in a previous GWAS of  OM9,22. In order to identify common biological processes between PLG and other 
loci associated with OM, this list of 32 genes was uploaded into NetworkAnalyst 3.0 and mapped (Reactome; 
Supplementary Figure S3A)23–25. In the resulting network, SP3 and PLG were the two largest nodes and were 
joined by 4 different nodes: SERPINE1, FN1, IGFBP3, and EP300. A secondary network was then mapped from 
the gene list: SP3, PLG, SERPINE1, FN1, IGFBP3, and EP300 (GO:BP; Supplementary Figure S3B). The most 
significant pathways identified within these networks from the Reactome database were “dissolution of fibrin 
Figure 2.  Four multi-ethnic families with the PLG c.782G > A (p.Arg261His), c.2045 T > A (p.Ile682Asn) and 
c.1414G > A (p.Asp472Asn) variants. (A) In Minnesota family UMN5014a, the c.2045 T > A (p.Ile682Asn) 
variant co-segregates with OM, however two unaffected individuals carry the c.1414G > A (p.Asp472Asn) 
variant. (B) Three Finnish families have the c.782G > A (p.Arg261His) variant.
Table 2.  Transmission disequilibrium test for PLG variants in 314 US trios. 1 For UTMB59, the father 
transmitted the minor allele for both c.112A > G (p.Lys38Glu) and c.1414G > A (p.Asp472Asn) variants to the 
child. On the other hand, for each of two trios UTMB132 and UTMB206 one parent carried both c.112A > G 
(p.Lys38Glu) and c.1414G > A (p.Asp472Asn) variants but did not transmit the minor alleles to the child.
Variant White Hispanic Black Mixed/Other Transmitted Non-transmitted TDT p
p.Lys38Glu 232 44 21 17 3 4 0.71
p.Arg261His 30 3 0 7 0 0 –
p.Ala494Val 49 7 2 9 0 1 0.31
p.Ile682Asn 190 41 22 10 1 0 0.32
p.Asp472Asn 221 44 23 17 101 116 0.31
All  variants1 215 43 21 17 104 119 0.32
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clot”, “platelet degranulation” and “response to elevated platelet cytosolic  Ca2+” (Supplementary Table S3), which 
are related to the known functions of plasminogen in fibrinolysis.
16S rRNA sequencing and analyses of middle ear and nasopharyngeal samples from OM 
patients in the US according to carriage of the c.1414G > A (p.Asp472Asn) variant. We also per-
formed microbiome sequencing and analyses of the middle ears and nasopharynges of carriers of the c.1414G > A 
(p.Asp472Asn) variant compared to wildtype individuals, however we found no significant differences in overall 
microbiome composition based on α-diversity indices (Supplementary Table 1). Only Bifidobacterium had an 
increased relative abundance in the nasopharynx of variant carriers (nominal p = 0.0024), which was non-sig-
nificant after correction for multiple testing (false discovery rate/FDR-adjusted p = 0.13; Supplementary Fig. 1). 
Unfortunately, we do not have saliva, middle ear or microbial samples for probands with the rare PLG variants.
Predicted effect of three rare variants on PLG protein. All three novel variants [c.782G > A 
(p.Arg261His), c.1481C > T (p.Ala494Val) and c.2045  T > A (p.Ile682Asn)] are located near disulfide bonds 
between cysteine residues (Cys166-Cys243, Cys483-Cys524, and Cys548-Cys666 respectively) that are poten-
tially important for protein  stabilization26. More specifically, these disulfide bonds are important for the struc-
ture and interface between domains. If these bonds are impacted by these variants, the stability and enzymatic 
activity of the whole protein could be  affected27,28.
The c.2045 T > A (p.Ile682Asn) variant is within the β-chain of the trypsin domain near the “94-shunt” sur-
face loop which is an important component in the accessibility of the catalytic triad residues that are necessary 
for trypsin-like protease  activity29. The 6-residue difference between the typical “99-loop” of serine proteases 
and the “94-shunt” in PLG is predicted to be an important factor in its increased range of  specificity30. In the 
native form, the isoleucine at this position forms an H-bond with Pro593 (Supplementary Fig. 2A) whereas the 
asparagine variant is predicted to form two extra H-bonds with Cys567 and Pro683 (Supplementary Fig. 1B). 
Due to this variant, there is a potential decrease in the accessibility of the catalytic triad that mediates the main 
enzymatic function of the protein.
The c.782G > A (p.Arg261His) variant occurs within the kringle 2 (KR2) domain of the PLG α-chain and 
could disrupt the single disulfide bond that serves as the interface between the KR2 and KR3 domains. The closed 
conformation of the native PLG, where fibrin is bound and less active, is in part stabilized by a chloride ion bond 
located near  Arg26126,31. The histidine variant is predicted to interfere with this chloride ion bond and destabilize 
the protein (Supplementary Fig. 2C–D). Additionally other previously identified variants within this region have 
been predicted to interfere with the interface between the serine protease domain and  KR232.
The c.1481C > T (p.Ala494Val) variant occurs within the KR5 domain of the β-chain26. The KR5 domain is 
crucial for the change in conformation from closed to open via fibrin binding to the lysine binding sites present 
in this  domain31. There were no changes in the H-bonds observed for this variant compared to the native protein 
and based on the location of the valine variant, the effect of the extra side chain on the valine is predicted to be 
minimal (Supplementary Fig. 2E–F).
Discussion
We identified four rare variants and one common variant within PLG in probands with OM. The PLG variants 
c.112A > G (p.Lys38Glu) or c.1414G > A (p.Asp472Asn) co-segregate with OM in two out of five families with 
multiple affected relatives (Fig. 1; Fig. 2A), but we do not have additional evidence from trio or expression stud-
ies to support association between these variants and OM. In a previous GWAS, the heterozygous genotype for 
c.112A > G (p.Lys38Glu) was a risk factor for OM. Additionally this variant was often found to be co-inherited 
in cis with c.1414G > A (p.Asp472Asn), which was previously associated with increased susceptibility to fungal 
infection in  mice33. However we did not see an association between any of the five identified PLG variants and 
OM in our trios (Table 2). It might be that these variants have weak effects that are only detectable in very large 
cohorts, e.g. with an OR of 1.43 for the p.Lys38Glu variant, we would need > 16,000 trios to detect a risk  effect19. 
Furthermore, our families with OM may have other common or rare variants in other genes that have stronger 
phenotypic effects, whether risk or protective variants, and are concealing the effect of these PLG variants.
Hereditary plasminogen deficiency with reduced protein activity is referred to as Type 1 Plasminogen Defi-
ciency (MIM 217090). This disease is inherited in an autosomal recessive manner, and most commonly mani-
fests as ligneous conjunctivitis, in which the wood-like pseudomembranous lesions develop on the mucous 
membranes in the  eyes34,35. Furthermore, similar lesions have been observed on the skin and other mucous 
membranes including the middle ear, gingiva, respiratory tract, and gastrointestinal or female genital tract, 
with OM occurring in 14% of patients with plasminogen deficiency. Notably none of the PLG carriers among 
our families have these lesions. PLG c.112A > G (p.Lys38Glu) is the most commonly identified variant in 34% 
of patients with type 1 plasminogen deficiency, whether as homozygous or compound  heterozygous12. However 
individuals with either homozygous or compound heterozygous genotypes for c.112A > G (p.Lys38Glu) may 
have decreased serum plasminogen activity and may also be  healthy10. We also considered the possibility that 
the known PLG variants are only causal of susceptibility when inherited in an autosomal recessive manner. 
However in the few individuals in the Colorado cohort that are homozygous for c.1414G > A (p.Asp472Asn), 
we did not see a difference in salivary PLG expression or α-diversity in microbial samples compared to wildtype 
or heterozygous (Supplementary Table 1). Likewise, none of the affected individuals in our families appear to be 
compound heterozygous for PLG variants.
Plasminogen has a potential role in pathogenic invasion by bacteria that bind it and thus can activate fibrin 
degradation to aid entry via cell  junctions11. It is not uncommon for pathogens to use the host plasminogen 
activation system as a means of invasion and many bacteria with PLG receptors have been identified, including 
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Haemophilus influenzae and Streptococcus pneumoniae36,37. Bifidobacterium is a common probiotic for use in 
preventing recurrent acute OM though its efficacy is  unproven38. Additionally, a previous study did not detect 
Bifidobacterium as having a significant role in acute OM, suggesting it may be a commensal colonizer of the 
 nasopharynx39. Thus the increased relative abundance of Bifidobacterium in the c.1414G > A (p.Asp472Asn) vari-
ant as compared to the wild-type does not corroborate previous findings that this common variant is associated 
with reduced risk of OM.
In human and mouse middle ear tissue PLG expression was low. Additionally, plasminogen activator activity 
could not be detected in middle ear effusion samples from adult  patients40. However, in the mouse middle ear 
study reported here, expression of the plasminogen activator gene (Plat) is upregulated in the middle ear six hours 
after NTHi inoculation, suggesting some Plg activity within middle ear. Plasminogen is a blood protein that is 
essential for wound healing, including healing of tympanic membrane  perforations41. This is further supported by 
our network analyses (Supplementary Table 3), wherein the most significant pathways linking PLG to other OM 
susceptibility genes involve processes for coagulation and cell adhesion which are both important for healing of 
injured tissues. In plasminogen-deficient patients, ligneous lesions primarily develop on the tympanic membrane, 
rather than the middle ear mucosa or  cavity42. Unfortunately, we do not have data from the tympanic membrane. 
There could be other proteins such as activators or binding partners involved that result in PLG having an indirect 
effect on OM susceptibility. For example, in the GTEx database the common c.1414G > A (p.Asp472Asn) variant 
is an eQTL for a lincRNA in esophageal mucosa, suggesting other potential disease mechanisms for PLG vari-
ants such as epigenetic regulation. These are however outside the scope of this study. Because PLG is secreted by 
the cell, it is possible that the protein is active in circulation and in the middle ear space, as shown by previous 
studies involving mice and secretion assays for other rare  variants12,14.
Interestingly, in COS-7 cells transfected with PLG mutants, secretion kinetics of both the c.112A > G 
(p.Lys38Glu) and c.1414G > A (p.Asp472Asn) variants were similar to the wild-type  control12. This further sup-
ports the finding that the effects of these two variants on OM susceptibility are very weak to none. On the other 
hand, in vitro transfection of COS-7 cells from other variants including missense substitutions of arginine 
resulted in decreased cell secretion of PLG, suggesting that other novel variants are potentially  functional12.
Three rare, heterozygous PLG variants, c.782G > A (p.Arg261His), c.1481C > T (p.Ala494Val) and c.2045T > A 
(p.Ile682Asn), were identified in US and Finnish families with OM. Two of these variants are predicted to change 
conformation of the protein and either affect enzymatic function or ligand binding (Supplementary Fig. 2). A 
previously reported variant c.782G > A (p.Arg261His) was identified in both cases and controls with multiple 
 sclerosis43, but is novel for OM. A variant at the same amino acid position p.Arg261Cys was identified in a family 
with all heterozygous individuals having reduced PLG levels to 64–68%44. This might suggest that c.782G > A 
(p.Arg261His), and other rare variants in PLG, are likely to be functional or pathogenic. Additionally, previ-
ously reported PLG variants that affect secretion kinetics in COS-7 cells fall within the same domains as the 
novel PLG variants reported  here12: variant c.2045 T > A (p.Ile682Asn) occurs within the β-chain of the trypsin 
domain, c.1481C > T (p.Ala494Val) within the KR5 domain of the β-chain, and c.782G > A (p.Arg261His) fall 
within the kringle 2 (KR2) domain of the α-chain45. All three domains in which these identified variants occur 
harbor previously reported variants that affect secretion of PLG. Due to the rarity of these three novel variants, 
their effects on tissue expression or the microbiome cannot be assessed at present.
To conclude, we identified three novel rare, missense variants and two known PLG variants which co-segregate 
with OM in some, but not all of our families with these variants. We hypothesized that these variants may play 
a role in OM susceptibility, however there was no association between these PLG variants and OM in our trios. 
Although the novel rare variants we identified might have potential effects on protein structure based on molecu-
lar modeling, PLG expression is very low or absent in normal or diseased middle ear tissues in both mouse and 
human. Our previous studies support a common mechanism by which the OM susceptibility variant affects 
expression of the encoded protein and other genes downstream, which in turn shifts the middle ear microbiome 
by changing the overall biodiversity or relative abundance of specific pathogens or commensal  taxa16,21,46,47. The 
mostly negative results of our multiple studies showed that this disease mechanism does not apply to PLG vari-
ants in relation to OM susceptibility in humans. Based on the Plg-knockout mouse model with chronic OM and 
non-healing eardrum perforations, PLG variants may act on the healing process within the tympanic membrane 
or the secretion of plasminogen into the middle ear cavity through other disease mechanisms, including epi-
genetic, that are not detectable by the methods used in this study. However such effects are easily concealed by 
other stronger factors contributing to OM susceptibility within the middle ear mucosa, including other risk or 
protective variants with larger phenotypic effects in our families. Our results underline the importance of follow-
ing up findings from genome-wide association through replication studies, preferably using multi-omic datasets.
Materials and methods
ethics approval. Guidelines from the Declaration of Helsinki were followed throughout the conduct of this 
study. Prior to start of the study, ethical approval was obtained from the following institutional review boards 
(IRB): Bahauddin Zakariya University; Colorado Multiple IRB; Helsinki University Hospital; University of Mar-
yland Baltimore; University of Minnesota; University of Texas Medical Branch (UTMB) Galveston; University of 
Virginia; and University of Washington. Informed consent was obtained from all adult participants and parents 
of children enrolled in the study. In addition, approval was obtained from the Institutional Animal Care and Use 
Committee of the Veterans Affairs Medical Center, San Diego, California. All experiments were performed in 
accordance with the Animal Welfare Act and the Health Research Extension Act of 1985.
Subject ascertainment. Except in Pakistan, OM-affected families from different cohorts were first identi-
fied upon referral of a child or proband for OM surgery (Supplementary Table 2). Samples were obtained from 
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previously established family cohorts for OM, including 257 trios from Texas, 85 trios from Colorado, 140 fami-
lies from Minnesota, 217 families from Finland, and 19 families from Pakistan. For Texan and Coloradan trios, 
clinical data from the proband including age, sex, breastfeeding history, allergic history, OM status and surgical 
technique, and saliva samples from both proband and parents were obtained. All saliva samples were collected 
using Oragene DNA collection kits and DNA was isolated using the manufacturer’s protocol.
In the three cohorts from Minnesota, Finland and Pakistan, DNA was extracted from blood samples provided 
by family members who participated in the study. These families were characterized as previously  described16,48. 
In Minnesota, all family members were examined by an otolaryngologist and tested by tympanometry for middle 
ear function, and family members were considered affected if ≥ 2 data sources, whether otoscopy, tympanometry, 
medical records, or personal history, were positive for OM. For Finnish families, clinical data, including history 
of OM, risk factors for OM, and otolaryngologic surgery, were obtained. Finnish individuals were considered 
positive for OM if they had insertion of tympanostomy tubes, effusive OM for > 2 months, or recurrent OM 
(i.e., > 3 episodes in 6 months or > 4 episodes in 12 months). Families from Pakistan were identified through 
referral for familial occurrence of OM. For Pakistani families, age at onset and recurrence of OM episodes were 
determined from medical history and OM status by otoscopy. For all cohorts, individuals with known genetic, 
craniofacial, and immunodeficiency syndromes were excluded.
DnA sequencing. DNA samples from individuals with OM from 28 Minnesota, 217 Finnish, and 14 
Pakistani families were submitted for exome sequencing using an Illumina HiSeq instrument, at an average 
40–60 × coverage. For the Minnesota and Finnish families, sequence capture was performed at the University 
of Washington using the Roche NimbleGen SeqCap EZ Human Exome Library v.2.0. For the Pakistani fami-
lies, exome sequencing was performed at the University of Maryland and genomic libraries were recovered for 
exome enrichment using the Agilent SureSelect Human Expanded All Exon V5 (62 Mb) kit. For all exome data, 
alignment and variant calling were performed using Burrows-Wheeler  Aligner49and Genome Analysis  Toolkit50, 
respectively.
Sanger sequencing was used to confirm co-segregation of five PLG variants (NM_00301.3) identified in exome 
data from nine multi-ethnic families (Table 1). An additional 70 Coloradan trios, 246 Texan trios, 1 Finnish fam-
ily, 2 Minnesota families, and 1 Pakistani family without exome data were Sanger-sequenced for the PLG variants.
Bioinformatic and statistical analyses. PLG variants found in exome data from OM-affected individuals 
were selected based on whether they are predicted to be damaging according to bioinformatic tools, including the 
scaled Combined Annotation-Dependent Depletion (CADD) score ≥ 15.051,  FATHMM52,  MutationAssessor53, 
 MutationTaster54,  PolyPhen255,  PROVEAN56,  SIFT57, MetaLR and MetaSVM from  dbNSFP58,59. Variants pre-
dicted to be damaging were further filtered for rare minor allele frequency (MAF < 1%), with the exception of 
common variant c.1414G > A (p.Asp472Asn), which was previously found to be co-inherited with c.112A > G 
(p.Lys38Glu). A Transmission Disequilibrium Test (TDT) was performed using genotypes for PLG variants 
c.782G > A (p.Arg261His) and c.1481C > T (p.Ala494Val) for Coloradan trios, and c.112A > G (p.Lys38Glu), 
c.1414G > A (p.Asp472Asn) and c.2045 T > A (p.Ile682Asn) for Coloradan and Texan  trios18.
For 314 families with PLG variants, non-genetic variables such as age, sex, ethnicity, breastfeeding history, 
previous diagnoses of allergy or asthma, and type of OM were investigated. Logistic regression analyses were 
performed with OM type (RAOM, COME) as outcome variable, carriage of PLG variants as independent vari-
able and other non-genetic variables as covariates. For Finnish probands, Fisher exact test was used to compare 
occurrence of RAOM vs. COME according to the PLG c.1414G > A (p.Asp472Asn) genotype. All variants tested 
were in Hardy–Weinberg equilibrium in the Texan, Coloradan and Finnish probands.
RnA expression in infected mouse middle ear. PLG expression in the mouse middle ear was derived 
from microarray analysis of mRNA from wild-type mice with acute OM after inoculation with non-typeable H. 
influenzae (NTHi) compared to healthy control mice, as described  previously20. In order to discover genes that 
are regulated during acute OM, transbullar inoculation of the middle ears were performed on 320 WBxB6 F1 
hybrid mice with PBS (sham control) or NTHi. Two independent samples were generated for each time point 
after infection or PBS injection: 0 h (0 h, uninfected controls), 3 h, 6 h, 1 day (1d), 2d, 3d, 5d, and 7d, from initia-
tion of OM to resolution. RNA was profiled on Affymetrix mouse 430 2.0 whole-genome microarrays. A total 
of 3,605 genes, approximately 14.4% of the mouse genome, defined the signature of acute, NTHi-induced OM 
across time.
RnA expression in human saliva and middle ear. Salivary RNA samples were collected from 19 pedi-
atric patients undergoing OM surgery at the Children’s Hospital Colorado (CHCO) and submitted for RNA 
sequencing, as previously  described21. In brief, RNA samples were processed with the NuGen Trio RNA-Seq 
Kit (Tecan, Redwood City, CA, USA) at the University of Colorado Denver Genomics and Microarray Core and 
sequenced on an Illumina HiSeq 4,000 with average ~ 31 million reads per sample. Reads were trimmed using 
the FASTX-Toolkit (v0.0.13) and aligned using STAR v2.5.3a60. Counts were normalized, summed and analyzed 
according to carriage of PLG variant c.1414G > A (p.Asp472Asn) using the Wilcoxon test.
Three cholesteatoma samples and four mucosa samples were collected from patients undergoing OM sur-
gery at the University of Colorado Hospital or CHCO. Samples were immediately isolated using the QIAGEN 
RNeasy Micro Kit. The tissue was initially homogenized with glass beads and QIAGEN buffer RLT, using a bead 
vortexer for 4 min. All four mucosa and three cholesteatoma samples passed QC and were submitted for RNA-
sequencing. Libraries were constructed using the NuGEN Trio RNA-Seq kit. Sequencing was completed on the 
Illumina NovaSeq, with paired-end 2 × 151 bp reads.
9Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15035  | https://doi.org/10.1038/s41598-020-70498-w
www.nature.com/scientificreports/
For human tissue samples, reads were trimmed with BBDuk v.38.5061. Salmon v0.13.1 was used to quantify 
the transcripts from the RNA-sequence  data62. Salmon was run in the mapping-based mode, which includes 
indexing and quantification. The Salmon index was created using the Ensembl release 96 GRCh38 human refer-
ence genome with a k-mer setting of 31. Transcript quantification was performed using the ‘–validateMappings’ 
flag. R was used to extract gene-summarized counts from the salmon quantification output, using the tximport 
 package63. Counts were filtered to have an average of more than 3 reads in either the cases or controls. Principal 
components (PC) plots were generated for each dataset. One sample (CHCO86) was removed from further 
analyses due to an insufficient mapping rate and not clustering with the other samples in the PC analysis. Counts 
were normalized using  DESeq264.
network analysis. Network analysis of PLG was performed with NetworkAnalyst 3.023–25. A list of 32 genes 
previously found to be associated with  OM22 and the IMEx Interactome generic protein–protein interaction 
database were used as input. Significant pathways were identified using the databases from the Kyoto Encyclope-
dia of Genes and Genomes (KEGG), Reactome, Gene Ontology (GO), and PANTHER via the Function Explorer 
tool in NetworkAnalyst. Functions associated with the network that had an FDR-adjusted p-value less than 0.05 
were considered significant.
Microbiome sequencing and analysis. 16S rRNA sequencing and microbiome analysis was performed 
for 42 middle ear and 77 nasopharyngeal samples from Coloradan individuals with OM. To construct the 16S 
amplicon library, broad-range amplification and sequence analysis of 16S rRNA genes to determine bacterial 
profiles were used with previously described  methods16. Analysis of the alpha-diversity indices of species rich-
ness, diversity, abundance and evenness (Chao1, Goods coverage, observed species index, Shannon Diversity 
Index) were tested for significance in association with PLG c.1414G > A genotype via t-test. Individual OTU 
associations were determined using Wilcoxon test for taxa that passed a prevalence threshold of 10% and relative 
abundance greater than 1%. R software was used for data analyses and generating figures.
Molecular modeling for rare PLG variants p.Arg261His, p.Ala494Val and p.Ile682Asn. For the 
three rare variants that we identified, protein models of PLG (PDB ID 4DUU) and the rare variants p.Arg261His, 
p.Ala494Val and p.Ile682Asn were constructed in Phyre2 and homology was visually analyzed and compared in 
DeepView/Swiss-PdbViewer65,66.
Data availability
Novel variants were deposited in ClinVar (accession numbers SCV000996504.1, SCV000996506.1, 
SCV000996507.1, VCV000013583.6 and VCV000692202.1). RNA-seq data from cholesteatoma and middle ear 
mucosal tissues are available in dbGaP phs001941.v1.p1. Demultiplexed paired-end 16S rRNA sequence data 
are accessible in the NCBI Short Read Archive under Accession Number PRJNA439435.
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